Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of JNJ-79635322 versus teclistamab in relapsed or refractory multiple myeloma
2025-522007-18-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing JNJ-79635322 with teclistamab (2 arms). Primary endpoints: overall response rate and progression-free survival. Planned start May 2026; status: authorised.
02
Drugs
ramantamigteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-522007-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522007-18-00.